SPONSOR
Beijing GoBroad Hospital
Total Trials
11
Recruiting
11
Phases
Phase 1, Phase 2, Phase 1
Conditions studied: Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary HypertensionT-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell MalignanciesT-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)Systemic Lupus Erythematosus (SLE)
Beijing GoBroad Hospital is a clinical research sponsor with 11 registered studies on ClinicalTrials.gov, of which 11 are actively recruiting participants. Research covers conditions including Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, T-cell Acute Lymphoblastic Leukemia.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beijing GoBroad Hospital
How many clinical trials has Beijing GoBroad Hospital sponsored?
ClinicalMetric currently tracks 11 clinical trials sponsored by Beijing GoBroad Hospital, of which 11 are actively recruiting participants. These trials cover conditions including Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beijing GoBroad Hospital research focus on?
Beijing GoBroad Hospital clinical trials span Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beijing GoBroad Hospital clinical trial?
To participate in a Beijing GoBroad Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beijing GoBroad Hospital trials with current recruitment status updated daily.
Clinical Trials by Beijing GoBroad Hospital
NCT06947460 Phase 1, Phase 2
Recruiting
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Refractory Lupus Nephritis
NCT06316427 Phase 1, Phase 2
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic Leukemia
NCT06925464 Phase 1, Phase 2
Recruiting
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
T-Cell Non-Hodgkin Lymphoma
NCT06585514 Phase 1, Phase 2
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
NCT07179484
Recruiting
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
NCT06326021 Phase 1
Recruiting
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Refractory/Relapsed Acute Myeloid Leukaemia
NCT06618313
Recruiting
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
B-Cell Non-Hodgkin Lymphoma-Recurrent
NCT06326008 Phase 1
Recruiting
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
B-cell Acute Lymphoblastic Leukemia
NCT07143617
Recruiting
Exploratory Clinical Study on the Safety of STR-P004
Autoimmune Diseases
NCT06343090
Recruiting
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
B-cell Acute Lymphoblastic Leukemia
NCT06688799 Phase 1, Phase 2
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Autoimmune Diseases
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology